Abiopharma

PERMIAN BASIN ROYALTY TRUST ANNOUNCES APRIL CASH DISTRIBUTION, EXCESS COST POSITION ON WADDELL RANCH PROPERTIES AND UNITHOLDER MAILING BY SOFTVEST

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

Abacus Global Management to Participate in the 2026 Milken Institute Global Conference

McKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutions

ASML reports transactions under its current share buyback program

Motorola Solutions Redefines Crime Center Operations, Centering Workflows Around Measurable “Missions”

Hadron Energy Aligns Valuation for Business Combination to $600M, Signaling Long-Term Market Discipline After GigCapital7 Form S-4 Registration Statement Declared Effective

Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET

Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update